FDA Tells MEI and Kyowa Kirin to Conduct Phase 3 Trial Before It Will Consider Accelerated Approval for Lymphoma Drug

The FDA has told MEI Pharma and Kyowa Kirin that they will need to provide more than results from a single-arm phase 2 study on their oral lymphoma drug candidate…

Continue ReadingFDA Tells MEI and Kyowa Kirin to Conduct Phase 3 Trial Before It Will Consider Accelerated Approval for Lymphoma Drug

FDA Amends GSK’s/Vir’s Sotrovimab EUA After Studies Show the Antibody Isn’t Effective Against New Omicron Variant

The U.S. government is pulling GlaxoSmithKline’s and Vir Technology’s investigational monoclonal antibody for COVID-19 from certain states where cases of the new subvariant of Omicron, BA.2, are high, as tests…

Continue ReadingFDA Amends GSK’s/Vir’s Sotrovimab EUA After Studies Show the Antibody Isn’t Effective Against New Omicron Variant